CGM as Diagnostic Tool in Observing Steroid-Induced Hyperglycemia (NCT06628284) | Clinical Trial Compass
CompletedNot Applicable
CGM as Diagnostic Tool in Observing Steroid-Induced Hyperglycemia
United States71 participantsStarted 2024-04-17
Plain-language summary
This study is designed to help understand how certain steroid medications affect blood sugar levels in patients undergoing pain management treatments. Patients who receive steroid injections for conditions like back pain or arthritis experience temporary high blood sugar (called steroid-induced hyperglycemia, SIH), which can sometimes lead to complications, especially in patients with diabetes. This study aims to understand this by monitoring blood glucose levels using continuous glucose monitors (Dexcom G7). The main goal of this study is to track how steroid injections impact blood sugar levels in patients.
Who can participate
Age range
19 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 19-75 years
* Patients meeting the medical criteria for need of interventional pain management procedure requiring corticosteroid administration.
* Willing and able to use Dexcom\'s CGM device.
* Willing to install Dexcom G7 app in their phone and register it for cloud data sharing
* Able to understand and sign informed consent
Exclusion Criteria:
* Pregnancy or lactation
* Medically unmanaged diabetes
* History of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS)
* History of severe hypoglycemia
* Active infection
* History of a liver disorder (ALT \> threefold of the ULN)
* History of any renal disease
* Immune compromised patient
* Active illegal drug user (self-reported)
* Under any other steroid treatment
* Any other medical condition or treatment that would make participation in the study unsafe or infeasible.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Spike in blood glucose level (hyperglycemic phase)
Timeframe: From baseline (day 0) to end of monitoring (day 10)
2
Duration of hypo- or hyperglycemia
Timeframe: From baseline (day 0) to end of monitoring (day 10)
3
Drop in blood glucose levels (hypoglycemic phase)
Timeframe: From baseline (day 0) to end of monitoring (day 10)